ArticleCancer biotherapy & radiopharmaceuticals2018
Exploration of a F(ab')
Article in Cancer biotherapy & radiopharmaceuticals, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 12 citations in OpenAlex.
- Lead radionuclides for theranostic applications in nuclear medicine: from atom to bedside.Theranostics · 2026Review
- Preclinical Evaluation of PTK7-Targeted Radionuclide Therapy.Molecular cancer therapeutics · 2025Article
- Review
- Antigen targeting and anti-tumor activity of a novel anti-CD146Scientific reports · 2024Article
- Combining Cisplatin with Different Radiation Qualities-Interpretation of Cytotoxic Effects In Vitro by Isobolographic Analysis.Pharmaceuticals (Basel, Switzerland) · 2023Article
- A Novel Single-Step-LabeledMaterials (Basel, Switzerland) · 2021Article
- Nanoradiopharmaceuticals Based on Alpha Emitters: Recent Developments for Medical Applications.Pharmaceutics · 2021Review
- Overview of the Most Promising Radionuclides for Targeted Alpha Therapy: The "Hopeful Eight".Pharmaceutics · 2021Review
- Perspectives on metals-based radioimmunotherapy (RIT): moving forward.Theranostics · 2021Review
- Development of Targeted Alpha Particle Therapy for Solid Tumors.Molecules (Basel, Switzerland) · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Refinement of treatment regimens enlisting targeted α-radiation therapy (TAT) is an ongoing effort. Among the variables to consider are the target molecule, radionuclide, dosage, and administration route. The panitumumab F(ab')
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.